Cargando…
Industry perspectives on biomarker qualification
Biomarkers have the potential to expedite drug development, increase patient safety, and optimize clinical response. Yet few have achieved regulatory qualification. A survey was conducted to clarify industry's perspective on biomarker qualification and identify the most promising biomarkers for...
Autores principales: | Lavezzari, G, Womack, AW |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065241/ https://www.ncbi.nlm.nih.gov/pubmed/26378777 http://dx.doi.org/10.1002/cpt.264 |
Ejemplares similares
-
Perspectives on statistical strategies for the regulatory biomarker qualification process
por: Hendrix, Suzanne B, et al.
Publicado: (2021) -
Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020
por: Bakker, Elisabeth, et al.
Publicado: (2022) -
FSI qualification and results
por: Rude, Vivien
Publicado: (2019) -
Biomarkers for Alzheimer’s Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation
por: Cummings, Jeffrey, et al.
Publicado: (2022) -
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
por: Stephenson, Diane, et al.
Publicado: (2019)